Abstract 1134: The LSD1 inhibitor INCB059872 is a possible therapeutic option for venetoclax-resistant AML

MLA

Antony Chadderton, et al. “Abstract 1134: The LSD1 Inhibitor INCB059872 Is a Possible Therapeutic Option for Venetoclax-Resistant AML.” Cancer Research, vol. 81, July 2021, p. 1134. EBSCOhost, https://doi.org/10.1158/1538-7445.am2021-1134.

APA

Antony Chadderton, Wenqing Yao, Liangxing Wu, Matthew C. Stubbs, Sang Hyun Lee, Holly Koblish, Melody Diamond, & Chunhong He. (2021). Abstract 1134: The LSD1 inhibitor INCB059872 is a possible therapeutic option for venetoclax-resistant AML. Cancer Research, 81, 1134. https://doi.org/10.1158/1538-7445.am2021-1134

Chicago

Antony Chadderton, Wenqing Yao, Liangxing Wu, Matthew C. Stubbs, Sang Hyun Lee, Holly Koblish, Melody Diamond, and Chunhong He. 2021. “Abstract 1134: The LSD1 Inhibitor INCB059872 Is a Possible Therapeutic Option for Venetoclax-Resistant AML.” Cancer Research 81 (July): 1134. doi:10.1158/1538-7445.am2021-1134.